Speaker Profile
Ph.D., Executive Chair, Enhanced Genomics
Biography
Dietrich is a highly experienced biotechnology industry leader, with technical expertise in high-throughput and translational genomics and a proven track record in scaling, financing, and leading companies. He has held multiple C-level and board roles, overseen successful exits and acquisitions, and played a central role in developing over two dozen private and public biotech companies, several of which went on to achieve billion-dollar valuations. Dietrich has also led world-leading high-throughput genomic infrastructure programs and contributed to the development of technologies for identifying genetic variants in both rare and common diseases. Dietrich is currently serving as CEO of Seyltx. Dietrich was previously Chairman of Peptilogics and Pendulum, and held leadership roles and Navigenics (acquired by Life Technologies) and Genia Technologies (acquired by Roche), among many others.
Talk
Illuminating the Dark Genome to Identify New Therapeutic Targets
Our proprietary 3D multiomics technology maps all disease-associated variants to genes, revealing 50% more potential drug targets for complex diseases. This gives us more targets to choose from and adds greater genetic validation to the targets we identify, reducing risk. We identify high confidence target genes 10x faster than traditional approaches.
AI for Emerging Therapeutics Showcase:
Enhanced Genomics
Enhanced Genomics is redefining drug target discovery by converting vast disease-associated genetic variant datasets into causal biology, delivering high-confidence, genetically validated drug targets for common diseases using a proprietary, cell-type-specific 3D multi-omics platform
Session Abstract – PMWC 2026 Silicon Valley
The PMWC 2026 AI for Emerging Therapeutics Showcase will provide a 15-30 minute time slot for selected companies to explore the transformative role of artificial intelligence in accelerating the discovery, development, and optimization of novel therapeutic modalities. From predictive algorithms for drug efficacy to real-time analysis in clinical trials, AI is revolutionizing the way we approach emerging therapies, including RNA-based treatments, gene editing, and personalized medicine. Industry leaders and experts will discuss AI-driven advancements, collaborative frameworks, and the challenges of integrating cutting-edge technologies into therapeutic innovation. Join us for an in-depth look at how AI is shaping the future of breakthrough therapeutics.
